Vasopressin in health and disease with a focus on affective disorders

Central Nervous System Agents in Medicinal Chemistry

Volumn 12, Issue 4, 2012, Pages 286-303

  Zelena, Dóra ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Anxiety; Depression; Elevated plus maze; Forced swim; Stress; Vasopressin; Vasopressin receptors

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY) BENZOYL] 4 PIPERIDYL] 1, 2, 3, 4 TETRAHYDRO 2 QUINOLINONE; 1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CL 385004; CONIVAPTAN; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DESMOPRESSIN; F 180; FE 202158; FLUOXETINE; JTV 605; LIXIVAPTAN; MORPHINE; MOZAVAPTAN; NELIVAPTAN; NEUROTRANSMITTER; PHE2OVT; PLACEBO; PROOPIOMELANOCORTIN; RELCOVAPTAN; SATAVAPTAN; TOLVAPTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN; VASOPRESSIN RECEPTOR AGONIST; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR; VP 343;

ACTH SECRETING ADENOMA; ANXIETY; ASCITES; BEHAVIOR; BRAIN VASOSPASM; CEREBROVASCULAR ACCIDENT; DIABETES INSIPIDUS; DYSMENORRHEA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEART FAILURE; HEART INFARCTION; HUMAN; HYPONATREMIA; HYPOTENSION; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; INAPPROPRIATE VASOPRESSIN SECRETION; INTRAOCULAR HYPERTENSION; KIDNEY DISEASE; LIVER CIRRHOSIS; MENTAL DISEASE; MOOD DISORDER; NONHUMAN; PERSONALITY DISORDER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RAYNAUD PHENOMENON; REVIEW; SIGNAL TRANSDUCTION; STRESS;

EID: 84870165211     PISSN: 18715249     EISSN: 18756166     Source Type: Journal    
DOI: 10.2174/187152412803760609     Document Type: Review

References (220)

1. Young, L.J.; Flanagan-Cato L.M. Editorial comment: Oxytocin, vasopressin and social behavior. Horm. Behav., 2012, 61, 227-229.
2. Turner, R.A.; Pierce, J.G., du, V.V. The purification and the amino acid content of vasopressin preparations. J. Biol. Chem., 1951, 191, 21-28.
3. Frank, E.; Landgraf, R. The vasopressin system--from antidiuresis to psychopathology. Eur. J. Pharmacol., 2008, 583, 226-242.
4. Ledford, H. 'Monogamous' vole in love-rat shock. Nature, 2008, 451, 617.
5. Young, L.J. Being human: love: neuroscience reveals all. Nature, 2009, 457, 148.
6. Koen, N.; Stein, D.J. Pharmacotherapy of anxiety disorders: a critical review. Dialogues Clin. Neurosci., 2011, 13, 423-437.
7. Richelson, E. Pharmacology of antidepressants. Mayo. Clin. Proc., 2001, 76, 511-527.
8. Singleton, N.; Bumpstead, R.; O'Brien, M. Psychiatric morbidity among adults living in private households Office for National Statistics. Available at: www.statistics.gov.uk, 2000.
9. Keck, M.E. Corticotropin-releasing factor, vasopressin and receptor systems in depression and anxiety. Amino Acids, 2006, 31, 241-250.
10. Thomson, F., Craighead, M. Innovative approaches for the treatment of depression: targeting the HPA axis. Neurochem. Res., 2008, 33, 691-707.
11. Ring, R.H. The central vasopressinergic system: examining the opportunities for psychiatric drug development Curr. Pharm. Des., 2005, 11, 205-225.
12. Gruber, C.W.; Muttenthaler, M. Discovery of defense- and neuropeptides in social ants by genome-mining. PLoS One, 2012, 7, e32559.
13. Schimchowitsch, S.; Moreau, C.; Laurent, F.; Stoeckel, M.E. Distribution and morphometric characteristics of oxytocin- and vasopressin-immunoreactive neurons in the rabbit hypothalamus. J. Comp. Neurol., 1989, 285, 304-324.
14. Rhodes, C.H.; Morrell, J.I. Pfaff, D.W. Immunohistochemical analysis of magnocellular elements in rat hypothalamus: distribution and numbers of cells containing neurophysin, oxytocin, and vasopressin. J. Comp. Neurol., 1981, 198, 45-64.
15. Watkins, W.B.; Choy, V.J. Immunocytochemical study of the hypothalamo-neurohypophysial system. III. Localization of oxytocin- and vasopressin-containing neurons in the pig hypothalamus. Cell Tissue Res., 1977, 180, 491-503.
16. Buijs, R.M. Intra- and extrahypothalamic vasopressin and oxytocin pathways in the rat. Pathways to the limbic system, medulla oblongata and spinal cord. Cell Tissue Res., 1978, 192, 423-435.
17. Planas, B.; Kolb, P.E.; Raskind, M.A., Miller, M.A. Vasopressin and galanin mRNAs coexist in the nucleus of the horizontal diagonal band: a novel site of vasopressin gene expression. J. Comp. Neurol., 1995, 361, 48-56.
18. Hallbeck, M.; Hermanson, O.; Blomqvist, A. Distribution of preprovasopressin mRNA in the rat central nervous system. J. Comp. Neurol., 1999, 411, 181-200.
19. Rood, B.D.; De Vries, G.J. Vasopressin innervation of the mouse (Mus musculus) brain and spinal cord. J. Comp. Neurol., 2011, 519, 2434-2474.
20. Aguilera, G. Regulation of pituitary ACTH secretion during chronic stress. Front. Neuroendocrinol., 1994, 15, 321-350.
21. Murat, B.; Devost, D.; Andres, M.; Mion, J.; Boulay, V.; Corbani, M., Zingg, H.H.; Guillon, G. V1b and CRHR1 Receptor Heterodimerization Mediates Synergistic Biological Actions of Vasopressin and CRH. Mol. Endocrinol., 2012, 26, 502-520.
22. Wong, D.L.; Tai, T.C.; Wong-Faull, D.C.; Claycomb, R., Meloni, E.G., Myers, K.M., Carlezon, W.A., Jr., Kvetnansky, R. Epinephrine: A Short- and Long-Term Regulator of Stress and Development of Illness: A Potential New Role for Epinephrine in Stress. Cell Mol. Neurobiol., 2012, 32(5), 737-748.
23. Rubin, R.T. Pharmacoendocrinology of major depression. Eur. Arch. Psychiatry Neurol. Sci., 1989, 238, 259-267.
24. Dinan, T.G.; Scott, L.V. Anatomy of melancholia: focus on hypothalamic-pituitary-adrenal axis overactivity and the role of vasopressin. J. Anat., 2005, 207, 259-264.
25. Scott, L.V.; Dinan, T.G. Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression. Life Sci., 1998, 62, 1985-1998.
26. Scott, L.V.; Dinan, T.G. Vasopressin as a target for antidepressant development: an assessment of the available evidence. J. Affect Disord., 2002, 72, 113-124.
27. Michell, R.H.; Kirk, C.J.; Billah, M.M. Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin. Biochem. Soc. Trans., 1979, 7, 861-865.
28. Jard, S.; Barberis, C.; Audigier, S.; Tribollet, E. Neurohypophyseal hormone receptor systems in brain and periphery. Prog. Brain Res., 1987, 72, 173-1787.
29. Johnson, A.E.; Audigier, S.; Rossi, F.; Jard, S.; Tribollet, E.; Barberis, C. Localization and characterization of vasopressin binding sites in the rat brain using an iodinated linear AVP antagonist. Brain Res., 1993, 622, 9-16.
30. Tribollet, E.; Barberis, C.; Arsenijevic, Y. Distribution of vasopressin and oxytocin receptors in the rat spinal cord: sexrelated differences and effect of castration in pudendal motor nuclei. Neuroscience, 1997, 78, 499-509.
31. Ostrowski, N.L.; Lolait, S.J.; Young, W.S.; 3rd Cellular localization of vasopressin V1a receptor messenger ribonucleic acid in adult male rat brain, pineal, and brain vasculature. Endocrinology, 1994, 135, 1511-1528.
32. Szot, P.; Bale, T.L.; Dorsa, D.M. Distribution of messenger RNA for the vasopressin V1a receptor in the CNS of male and female rats. Brain Res. Mol. Brain Res., 1994, 24, 1-10.
33. Antoni, F.A.; Holmes, M.C.; Makara, G.B.; Karteszi, M.; Laszlo, F.A. Evidence that the effects of arginine-8-vasopressin (AVP) on pituitary corticotropin (ACTH) release are mediated by a novel type of receptor. Peptides, 1984, 5, 519-522.
34. Saito, M.; Tahara, A.; Sugimoto, T.; Abe, K.; Furuichi, K. Evidence that atypical vasopressin V(2) receptor in inner medulla of kidney is V(1B) receptor. Eur. J. Pharmacol., 2000, 401, 289-296.
35. Lolait, S.J.; O'Carroll, A.M.; Mahan, L.C.; Felder, C.C.; Button, D.C.; Young, W.S.; 3rd, Mezey, E.; Brownstein, M.J. Extrapituitary expression of the rat V1b vasopressin receptor gene Proc. Natl. Acad. Sci. U.S.A, 1995, 92, 6783-6787.
36. Saito, M.; Sugimoto, T.; Tahara, A.; Kawashima, H. Molecular cloning and characterization of rat V1b vasopressin receptor: evidence for its expression in extra-pituitary tissues. Biochem. Biophys. Res. Commun., 1995, 212, 751-757.
37. Vaccari, C.; Lolait, S.J.; Ostrowski, N.L. Comparative distribution of vasopressin V1b and oxytocin receptor messenger ribonucleic acids in brain. Endocrinology, 1998, 139, 5015-5033.
38. Hernando, F.; Schoots, O.; Lolait, S.J.; Burbach, J.P. Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin. Endocrinology, 2001, 142, 1659-1668.
39. Stemmelin, J.; Lukovic, L.; Salome, N.; Griebel, G. Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415. Neuropsychopharmacology, 2005, 30, 35-42.
40. Young, W.S.; Li, J.; Wersinger, S.R.; Palkovits, M. The vasopressin 1b receptor is prominent in the hippocampal area CA2 where it is unaffected by restraint stress or adrenalectomy. Neuroscience, 2006, 143, 1031-1039.
41. Kato, Y.; Igarashi, N.; Hirasawa, A.; Tsujimoto, G.; Kobayashi, M. Distribution and developmental changes in vasopressin V2 receptor mRNA in rat brain. Differentiation, 1995, 59, 163-169.
42. Monstein, H.J.; Truedsson, M.; Ryberg, A.; Ohlsson, B. Vasopressin receptor mRNA expression in the human gastrointestinal tract. Eur. Surg. Res., 2008, 40, 34-40.
43. Gimpl, G.; Fahrenholz, F. The oxytocin receptor system: structure, function, and regulation. Physiol. Rev., 2001, 81, 629-683.
44. de Kloet, E.R.; Voorhuis, D.A.; Boschma, Y.; Elands, J. Estradiol modulates density of putative 'oxytocin receptors' in discrete rat brain regions. Neuroendocrinology, 1986, 44, 415-421.
45. Fillion, C.; Malassine, A.; Tahri-Joutei, A.; Allevard, A.M.; Bedin, M.; Gharib, C.; Hugues, J.N.; Pointis, G. Immunoreactive arginine vasopressin in the testis: immunocytochemical localization and testicular content in normal and in experimental cryptorchid mouse. Biol. Reprod., 1993, 48, 786-792.
46. de Wied, D.; Bohus, B.; Ernst, A.M.; de Jong, W.; Nieuwehuizen, W.; Pieper, E.E.; Yasumura, S. Several aspects of the influence of vasopressin on pituitary-adrenal activity. Proc. R. Soc. Med., 1967, 60, 907-908.
47. Engelmann, M.; Landgraf, R.; Wotjak, C.T. The hypothalamicneurohypophysial system regulates the hypothalamic-pituitaryadrenal axis under stress: an old concept revisited. Front. Neuroendocrinol, 2004, 25, 132-149.
48. Zoli, M.; Torri, C.; Ferrari, R.; Jansson, A.; Zini, I.; Fuxe, K.; Agnati, L.F. The emergence of the volume transmission concept. Brain Res. Brain Res. Rev., 1998, 26, 136-147.
49. Leng, G.; Ludwig, M. Neurotransmitters and peptides: whispered secrets and public announcements. J. Physiol., 2008, 586, 5625-5632.
50. Ludwig, M.; Leng, G. Dendritic peptide release and peptidedependent behaviors. Nat. Rev. Neurosci., 2006, 7, 126-136.
51. Riphagen, C.L.; Pittman, Q.J. Spinal arginine vasopressin elevates renal nerve activity in the rat. J. Neuroendocrinol., 1989, 1, 339-344.
52. Lebrun, C.; Rohmeiss, P.; Demmert, G.; Rettig, R.; Unger, T. Central cardiovascular actions of vasopressin in the rat. Can. J. Physiol. Pharmacol., 1987, 65, 1712-1716.
53. Ermisch, A.; Brust, P.; Kretzschmar, R.; Ruhle, H.J. Peptides and blood-brain barrier transport. Physiol. Rev., 1993, 73, 489-527.
54. Banks, W.A.; Kastin, A.J.; Horvath, A.; Michals, E.A. Carriermediated transport of vasopressin across the blood-brain barrier of the mouse. J. Neurosci. Res., 1987, 18, 326-332.
55. Ivanova, L.N. Vasopressin: molecular mechanisms of antidiuretic effect. Ross Fiziol Zh Im I M Sechenova, 2011, 97, 235-262.
56. Hofbauer, K.G.; Studer, W.; Mah, S.C.; Michel, J.B.; Wood, J.M.; Stalder, R. The significance of vasopressin as a pressor agent. J. Cardiovasc. Pharmacol., 1984, 6 Suppl 2, S429-S438.
57. Akerlund, M.; Melin, P.; Maggi, M. Potential use of oxytocin and vasopressin V1a antagonists in the treatment of preterm labour and primary dysmenorrhoea. Adv. Exp. Med. Biol., 1995, 395, 595-600.
58. Landry, D.W.; Oliver, J.A. Increased complexity of vasopressin's vascular actions. Crit. Care, 2010, 14, 1011.
59. Serradeil-Le Gal, C.; Bourrie, B.; Raufaste, D.; Carayon, P.; Garcia, C.; Maffrand, J.P.; Le Fur, G.; Casellas, P. Effect of a new, potent, non-peptide V1a vasopressin antagonist, SR 49059, on the binding and the mitogenic activity of vasopressin on Swiss 3T3 cells. Biochem. Pharmacol., 1994, 47, 633-641.
60. Montero, S.; Mendoza, H.; Valles, V.; Lemus, M.; Alvarez-Buylla, R.; de Alvarez-Buylla, E.R. Arginine-vasopressin mediates central and peripheral glucose regulation in response to carotid body receptor stimulation with Na-cyanide. J. Appl. Physiol., 2006, 100, 1902-1909.
61. Quintanar-Stephano, A.; Organista-Esparza, A.; Chavira-Ramirez, R.; Kovacs, K.; Berczi, I. Effects of neurointermediate pituitary lobectomy and desmopressin on acute experimental autoimmune encephalomyelitis in lewis rats. Neuroimmunomodulation, 2012, 19, 148-157.
62. Richmond, C.A. The role of arginine vasopressin in thermoregulation during fever. J. Neurosci. Nurs., 2003, 35, 281-286.
63. rd Vasopressin: behavioral roles of an "original" neuropeptide. Prog. Neurobiol., 2008, 84, 1-24.
64. Reppert, S.M.; Schwartz, W.J.; Artman, H.G.; Fisher, D.A. Comparison of the temporal profiles of vasopressin and oxytocin in the cerebrospinal fluid of the cat, monkey and rat. Brain Res., 1983, 261, 341-345.
65. Buijs, R.M.; van Eden, C.G.; Goncharuk, V.D.; Kalsbeek, A. The biological clock tunes the organs of the body: timing by hormones and the autonomic nervous system. J. Endocrinol., 2003, 177, 17-26.
66. Oliver, P.L.; Sobczyk, M.V.; Maywood, E.S.; Edwards, B.; Lee, S.; Livieratos, A.; Oster, H.; Butler, R.; Godinho, S.I.; Wulff, K.; Peirson, S.N.; Fisher, S.P.; Chesham, J.E.; Smith, J.W.; Hastings, M.H.; Davies, K.E.; Foster, R.G. Disrupted circadian rhythms in a mouse model of schizophrenia. Curr. Biol., 2012, 22, 314-319.
67. Yang, J.; Yang, Y.; Chen, J.M.; Xu, H.T.; Liu, W.Y.; Wang, C.H.; Lin, B.C. Arginine vasopressin is an important regulator in antinociceptive modulation of hypothalamic paraventricular nucleus in the rat. Neuropeptides, 2007, 41, 165-176.
68. Yang, J.; Chen, J.M.; Liu, W.Y.; Song, C.Y.; Lin, B.C. Through V2, not V1 receptor relating to endogenous opiate peptides, arginine vasopressin in periaqueductal gray regulates antinociception in the rat. Regul. Pept., 2006, 137, 156-161.
69. Caldwell, H.K. Neurobiology of sociability. Adv. Exp. Med. Biol., 2012, 739, 187-205.
70. Godwin, J.; Thompson, R. Nonapeptides and social behavior in fishes. Horm. Behav., 2012, 61, 230-238.
71. Ferris, C.F.; Potegal, M. Vasopressin receptor blockade in the anterior hypothalamus suppresses aggression in hamsters. Physiol. Behav., 1988, 44, 235-239.
72. Blanchard, R.J.; Griebel, G.; Farrokhi, C.; Markham, C.; Yang, M.; Blanchard, D.C. AVP V1b selective antagonist SSR149415 blocks aggressive behaviors in hamsters. Pharmacol. Biochem. Behav., 2005, 80, 189-194.
73. Wersinger, S.R.; Caldwell, H.K.; Christiansen, M., Young, W.S. 3rd Disruption of the vasopressin 1b receptor gene impairs the attack component of aggressive behavior in mice. Genes Brain Behav., 2007, 6, 653-660.
74. Wersinger, S.R.; Caldwell, H.K.; Martinez, L.; Gold, P.; Hu, S.B.; Young, W.S., 3rd Vasopressin 1a receptor knockout mice have a subtle olfactory deficit but normal aggression. Genes Brain Behav., 2007, 6, 540-551.
75. Insel, T.R.; Wang, Z.X.; Ferris, C.F. Patterns of brain vasopressin receptor distribution associated with social organization in microtine rodents. J. Neurosci., 1994, 14, 5381-5392.
76. Wang, Z.; Ferris, C.F.; De Vries, G.J. Role of septal vasopressin innervation in paternal behavior in prairie voles (Microtus ochrogaster) Proc. Natl. Acad. Sci. U.S.A, 1994, 91, 400-404.
77. Bosch, O.J.; Neumann, I.D. Both oxytocin and vasopressin are mediators of maternal care and aggression in rodents: From central release to sites of action Horm. Behav., 2012, 61, 293-303.
78. Braida, D.; Donzelli, A.; Martucci, R.; Capurro, V.; Busnelli, M.; Chini, B.; Sala, M. Neurohypophyseal hormones manipulation modulate social and anxiety-related behavior in zebrafish Psychopharmacology (Berl), 2012, 220, 319-330.
79. Tobin, V.A.; Hashimoto, H.; Wacker, D.W.; Takayanagi, Y.; Langnaese, K.; Caquineau, C.; Noack, J.; Landgraf, R.; Onaka, T.; Leng, G.; Meddle, S.L.; Engelmann, M.; Ludwig, M. An intrinsic vasopressin system in the olfactory bulb is involved in social recognition. Nature, 2010, 464, 413-417.
80. Engelmann, M.; Landgraf, R. Microdialysis administration of vasopressin into the septum improves social recognition in Brattleboro rats. Physiol. Behav., 1994, 55, 145-149.
81. Wersinger, S.R.; Kelliher, K.R.; Zufall, F.; Lolait, S.J.; O'Carroll, A.M.; Young, W.S., 3rd Social motivation is reduced in vasopressin 1b receptor null mice despite normal performance in an olfactory discrimination task. Horm. Behav., 2004, 46, 638-645.
82. Wied, D. The influence of the posterior and intermediate lobe of the pituitary adn pituitary peptides on the maintenance of a conditioned avoidance response in rats. Int. J. Neuropharmacol., 1965, 4, 157-167.
83. Alescio-Lautier, B.; Rao, H.; Paban, V.; Devigne, C.; Soumireu-Mourat, B. Inhibition of the vasopressin-enhancing effect on memory retrieval and relearning by a vasopressin V1 receptor antagonist in mice. Eur. J. Pharmacol., 1995, 294, 763-770.
84. Subiah, C.O.; Mabandla, M.V.; Phulukdaree, A.; Chuturgoon, A.A.; Daniels, W.M. The effects of vasopressin and oxytocin on methamphetamine-induced place preference behavior in rats. Metab. Brain Dis., 2012, 27(3), 341-350.
85. Aarde, S.M.; Jentsch, J.D. Haploinsufficiency of the argininevasopressin gene is associated with poor spatial working memory performance in rats. Horm. Behav., 2006, 49, 501-508.
86. Mishima, K.; Tsukikawa, H.; Miura, I.; Inada, K.; Abe, K.; Matsumoto, Y.; Egashira, N.; Iwasaki, K.; Fujiwara, M. Ameliorative effect of NC-1900, a new AVP4-9 analog, through vasopressin V1A receptor on scopolamine-induced impairments of spatial memory in the eight-arm radial maze. Neuropharmacology, 2003, 44, 541-552.
87. Aguilera, G.; Rabadan-Diehl, C. Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation. Regul. Pept., 2000, 96, 23-29.
88. Lightman, S.L.; Windle, R.J.; Ma, X.M.; Harbuz, M.S.; Shanks, N.M.; Julian, M.D.; Wood, S.A.; Kershaw, Y.M.; Ingram, C.D. Hypothalamic-pituitary-adrenal function. Arch. Physiol. Biochem., 2002, 110, 90-93.
89. Tilders, F.J.; Berkenbosch, F.; Vermes, I.; Linton, E.A.; Smelik, P.G. Role of epinephrine and vasopressin in the control of the pituitary-adrenal response to stress. Fed. Proc., 1985, 44, 155-160.
90. Ono, N.; Bedran de Castro, J.; Khorram, O.; McCann, S.M. Role of arginine vasopressin in control of ACTH and LH release during stress. Life Sci., 1985, 36, 1779-1786.
91. Tanoue, A.; Ito, S.; Honda, K.; Oshikawa, S.; Kitagawa, Y.; Koshimizu, T.A.; Mori, T.; Tsujimoto, G. The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J. Clin. Invest., 2004, 113, 302-309.
92. Lolait, S.J.; Stewart, L.Q.; Jessop, D.S.; Young, W.S. 3rd, O'Carroll, A.M. The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. Endocrinology, 2007, 148, 849-856.
93. Lolait, S.J.; Stewart, L.Q.; Roper, J.A.; Harrison, G.; Jessop, D.S.; Young, W.S., 3rd, O'Carroll, A.M. Attenuated stress response to acute lipopolysaccharide challenge and ethanol administration in vasopressin V1b receptor knockout mice. J. Neuroendocrinol., 2007, 19, 543-551.
94. Serradeil-Le Gal, C.; Wagnon, J.; Simiand, J.; Griebel, G.; Lacour, C.; Guillon, G.; Barberis, C.; Brossard, G.; Soubrie, P.; Nisato, D.; Pascal, M.; Pruss, R.; Scatton, B.; Maffrand, J.P.; Le Fur, G. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2- methoxy-phenyl) -2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,Ndimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J. Pharmacol. Exp. Ther., 2002, 300, 1122-1130.
95. Ramos, A.T.; Troncone, L.R.; Tufik, S. Suppression of adrenocorticotrophic hormone secretion by simultaneous antagonism of vasopressin 1b and CRH-1 receptors on three different stress models. Neuroendocrinology, 2006, 84, 309-316.
96. Spiga, F.; Harrison, L.R.; Wood, S.; Knight, D.M.; MacSweeney, C.P.; Thomson, F.; Craighead, M.; Lightman, S.L. Blockade of the V(1b) receptor reduces ACTH, but not corticosterone secretion induced by stress without affecting basal hypothalamic-pituitaryadrenal axis activity. J. Endocrinol., 2009, 200, 273-283.
97. Spiga, F.; Harrison, L.R.; MacSweeney, C.P.; Thomson, F.J.; Craighead, M.; Lightman, S.L. Effect of vasopressin 1b receptor blockade on the hypothalamic-pituitary-adrenal response of chronically stressed rats to a heterotypic stressor. J. Endocrinol., 2009, 200, 285-291.
98. Smethurst, C.A.; Borthwick, J.A.; Gaines, S.; Watson, S.; Green, A.; Schulz, M.J.; Burton, G.; Buson, A.A.; Arban, R. The characterization of a novel V1b antagonist lead series. Bioorg. Med. Chem. Lett., 2011, 21, 92-96.
99. Chen, J.; Young, S.; Subburaju, S.; Sheppard, J.; Kiss, A.; Atkinson, H.; Wood, S.; Lightman, S.; Serradeil-Le Gal, C.; Aguilera, G. Vasopressin does not mediate hypersensitivity of the hypothalamic pituitary adrenal axis during chronic stress. Ann. N.Y. Acad. Sci., 2008, 1148, 349-359.
100. Valtin, H.; Schroeder, H.A. Familial Hypothalamic Diabetes Insipidus in Rats (Brattleboro Strain). Am. J. Physiol., 1964, 206, 425-430.
101. Lolait, S.J.; Markwick, A.J.; McNally, M.; Abraham, J.; Smith, A.I.; Funder, J.W. Anterior pituitary cells from Brattleboro (di/di), Long-Evans and Sprague-Dawley rats contain immunoreactive arginine vasopressin. Neuroendocrinology, 1986, 43, 577-583.
102. Bohus, B.; de Wied, D. The vasopressin deficient Brattleboro rats: a natural knockout model used in the search for CNS effects of vasopressin. Prog. Brain Res., 1998, 119, 555-573.
103. Brudieux, R.; Krifi, M.N.; Laulin, J.P. Release of aldosterone and corticosterone from the adrenal cortex of the Brattleboro rat in response to administration of ACTH. J. Endocrinol., 1986, 111, 375-381.
104. Burgess, W.J.; Balment, R.J. Plasma atrial natriuretic peptide in vasopressin deficiency: the effects of acute water deprivation in rats. J. Endocrinol., 1992, 135, 431-438.
105. Eckland, D.J.; Todd, K.; Lightman, S.L. Immunoreactive vasopressin and oxytocin in hypothalamo-hypophysial portal blood of the Brattleboro and Long-Evans rat: effect of adrenalectomy and dexamethasone. J. Endocrinol., 1988, 117, 27-34.
106. Zelena, D., Mergl, Z., Foldes, A., Kovacs, K.J., Toth, Z., Makara, G.B. Role of hypothalamic inputs in maintaining pituitary-adrenal responsiveness in repeated restraint. Am. J. Physiol. Endocrinol. Metab., 2003, 285, E1110-E1117.
107. Kjaer, A.; Knigge, U.; Bach, F.W.; Warberg, J. Impaired histamine- and stress-induced secretion of ACTH and beta-endorphin in vasopressindeficient Brattleboro rats. Neuroendocrinology, 1993, 57, 1035-1041.
108. Zelena, D.; Domokos, A.; Jain, S.K.; Jankord, R.; Filaretova, L. The stimuli-specific role of vasopressin in the hypothalamuspituitary-adrenal axis response to stress. J. Endocrinol., 2009, 202, 263-278.
109. Zelena, D.; Domokos, A.; Barna, I.; Mergl, Z.; Haller, J.; Makara, G.B. Control of the hypothalamo-pituitary-adrenal axis in the neonatal period: adrenocorticotropin and corticosterone stress responses dissociate in vasopressin-deficient brattleboro rats. Endocrinology, 2008, 149, 2576-2583.
110. Zelena, D.; Mergl, Z.; Makara, G.B. Glutamate agonists activate the hypothalamic-pituitary-adrenal axis through hypothalamic paraventricular nucleus but not through vasopressinerg neurons Brain Res., 2005, 1031, 185-193.
111. Zelena, D.; Filaretova, L.; Mergl, Z.; Barna, I.; Toth, Z.E.; Makara, G.B. Hypothalamic paraventricular nucleus, but not vasopressin, participates in chronic hyperactivity of the HPA axis in diabetic rats. Am. J. Physiol. Endocrinol. Metab., 2006, 290, E243-250.
112. Domokos, A.; Mergl, Z.; Barna, I.; Makara, G.B.; Zelena, D. Congenital vasopressin deficiency and acute and chronic opiate effects on hypothalamo-pituitary-adrenal axis activity in Brattleboro rats. J. Endocrinol., 2008, 196, 113-121.
113. Keck, M.E.; Welt, T.; Muller, M.B.; Uhr, M.; Ohl, F.; Wigger, A.; Toschi, N.; Holsboer, F.; Landgraf, R. Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacology, 2003, 28, 235-243.
114. Landgraf, R.; Wigger, A.; Holsboer, F.; Neumann, I.D. Hyperreactive hypothalamo-pituitary-adrenocortical axis in rats bred for high anxiety-related behavior. J. Neuroendocrinol., 1999, 11, 405-407.
115. Veenema, A.H.; Torner, L.; Blume, A.; Beiderbeck, D.I.; Neumann, I.D. Low inborn anxiety correlates with high intermale aggression: link to ACTH response and neuronal activation of the hypothalamic paraventricular nucleus. Horm. Behav., 2007, 51, 11-19.
116. Aubry, J.M.; Bartanusz, V.; Driscoll, P.; Schulz, P.; Steimer, T.; Kiss, J.Z. Corticotropin-releasing factor and vasopressin mRNA levels in roman high- and low-avoidance rats: response to openfield exposure. Neuroendocrinology, 1995, 61, 89-97.
117. Walker, C.D.; Rivest, R.W.; Meaney, M.J.; Aubert, M.L. Differential activation of the pituitary-adrenocortical axis after stress in the rat: use of two genetically selected lines (Roman low- and highavoidance rats) as a model. J. Endocrinol., 1989, 123, 477-485.
118. Spinedi, E.; Hadid, R.; Gaillard, R.C. Increased vasopressinergic activity as a possible compensatory mechanism for a normal hypothalamic-pituitary-adrenal axis response to stress in BALB/c nude mice. Neuroendocrinology, 1997, 66, 287-293.
119. Fuchs, E.; Fliugge, G. Experimental animal models for the simulation of depression and anxiety. Dialogues Clin Neurosci, 2006, 8, 323-333.
120. McArthur, R.; Borsini, F. Animal models of depression in drug discovery: a historical perspective. Pharmacol. Biochem. Behav., 2006, 84, 436-452.
121. El Yacoubi, M.; Vaugeois, J.M. Genetic rodent models of depression. Curr. Opin Pharmacol., 2007, 7, 3-7.
122. Porsolt, R.D.; Anton, G.; Blavet, N.; Jalfre, M. Behavioral despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol., 1978, 47, 379-391.
123. Wotjak, C.T.; Ganster, J.; Kohl, G.; Holsboer, F.; Landgraf, R.; Engelmann, M. Dissociated central and peripheral release of vasopressin, but not oxytocin, in response to repeated swim stress: new insights into the secretory capacities of peptidergic neurons. Neuroscience, 1998, 85, 1209-1222.
124. Ebner, K.; Wotjak, C.T.; Holsboer, F.; Landgraf, R.; Engelmann, M. Vasopressin released within the septal brain area during swim stress modulates the behavioral stress response in rats. Eur. J. Neurosci., 1999, 11, 997-1002.
125. Ebner, K.; Wotjak, C.T.; Landgraf, R.; Engelmann, M. Forced swimming triggers vasopressin release within the amygdala to modulate stress-coping strategies in rats. Eur. J. Neurosci., 2002, 15, 384-388.
126. Griebel, G.; Simiand, J.; Serradeil-Le Gal, C.; Wagnon, J.; Pascal, M.; Scatton, B.; Maffrand, J.P.; Soubrie, P. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc. Natl. Acad. Sci. U.S.A, 2002, 99, 6370-6375.
127. Veenema, A.H. Early life stress, the development of aggression and neuroendocrine and neurobiological correlates: what can we learn from animal models? Front. Neuroendocrinol, 2009, 30, 497-518.
128. Murgatroyd, C.; Spengler, D. Epigenetic programming of the HPA axis: early life decides. Stress, 2011, 14, 581-589.
129. Gunnar, M.R.; Fisher, P.A. Bringing basic research on early experience and stress neurobiology to bear on preventive interventions for neglected and maltreated children. Dev. Psychopathol., 2006, 18, 651-677.
130. Mlynarik, M.; Zelena, D.; Bagdy, G.; Makara, G.B.; Jezova, D. Signs of attenuated depression-like behavior in vasopressin deficient Brattleboro rats. Horm. Behav., 2007, 51, 395-405.
131. Wigger, A., Sanchez, M.M., Mathys, K.C., Ebner, K., Frank, E., Liu, D., Kresse, A., Neumann, I.D., Holsboer, F., Plotsky, P.M., Landgraf, R. Alterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety: critical role of vasopressin. Neuropsychopharmacology, 2004, 29, 1-14.
132. Cryan, J.F.; Slattery, D.A. Animal models of mood disorders: Recent developments. Curr. Opin Psychiatry, 2007, 20, 1-7.
133. Landgraf, R.; Kessler, M.S.; Bunck, M.; Murgatroyd, C.; Spengler, D.; Zimbelmann, M.; Nussbaumer, M.; Czibere, L.; Turck, C.W.; Singewald, N.; Rujescu, D.; Frank, E. Candidate genes of anxietyrelated behavior in HAB/LAB rats and mice: focus on vasopressin and glyoxalase-I. Neurosci. Biobehav. Rev., 2007, 31, 89-102.
134. Bielsky, I.F.; Hu, S.B.; Szegda, K.L.; Westphal, H.; Young, L.J. Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology, 2004, 29, 483-493.
135. Egashira, N.; Tanoue, A.; Matsuda, T.; Koushi, E.; Harada, S.; Takano, Y.; Tsujimoto, G.; Mishima, K.; Iwasaki, K.; Fujiwara, M. Impaired social interaction and reduced anxiety-related behavior in vasopressin V1a receptor knockout mice. Behav. Brain Res., 2007, 178, 123-127.
136. Bielsky, I.F.; Hu, S.B.; Ren, X.; Terwilliger, E.F.; Young, L.J. The V1a vasopressin receptor is necessary and sufficient for normal social recognition: a gene replacement study. Neuron, 2005, 47, 503-513.
137. Mak, P.; Broussard, C.; Vacy, K.; Broadbear, J.H. Modulation of anxiety behavior in the elevated plus maze using peptidic oxytocin and vasopressin receptor ligands in the rat. J. Psychopharmacol., 2012.
138. Amico, J.A.; Vollmer, R.R.; Karam, J.R.; Lee, P.R.; Li, X.; Koenig, J.I., McCarthy, M.M. Centrally administered oxytocin elicits exaggerated grooming in oxytocin null mice. Pharmacol. Biochem. Behav., 2004, 78, 333-339.
139. Landgraf, R.; Gerstberger, R.; Montkowski, A.; Probst, J.C.; Wotjak, C.T.; Holsboer, F.; Engelmann, M. V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxietyrelated behavior in rats. J. Neurosci., 1995, 15, 4250-4258.
140. Liebsch, G.; Wotjak, C.T.; Landgraf, R.; Engelmann, M. Septal vasopressin modulates anxiety-related behavior in rats. Neurosci. Lett., 1996, 217, 101-104.
141. Appenrodt, E.; Schnabel, R.; Schwarzberg, H. Vasopressin administration modulates anxiety-related behavior in rats. Physiol. Behav., 1998, 64, 543-547.
142. Caldwell, H.K.; Stewart, J.; Wiedholz, L.M.; Millstein, R.A.; Iacangelo, A.; Holmes, A.; Young, W.S. 3rd, Wersinger, S.R. The acute intoxicating effects of ethanol are not dependent on the vasopressin 1a or 1b receptors. Neuropeptides, 2006, 40, 325-337.
143. Amikishieva, A.V.; Ilnitskaya, S.I.; Nikolin, V.P.; Popova, N.A. Effect of vasopressin V1b receptor antagonist, SSR149415, on anxiety-like behavior and Lewis lung carcinoma metastasis in mice. Exp. Oncol., 2011, 33, 126-129.
144. Salome, N.; Stemmelin, J.; Cohen, C.; Griebel, G. Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats. Psychopharmacology (Berl), 2006, 187, 237-244.
145. Rotzinger, S.; Lovejoy, D.A.; Tan, L.A. Behavioral effects of neuropeptides in rodent models of depression and anxiety. Peptides, 2010, 31, 736-756.
146. Stewart, L.Q.; Roper, J.A.; Scott Young, W. 3rd, O'Carroll, A.M., Lolait, S.J. The role of the arginine vasopressin Avp1b receptor in the acute neuroendocrine action of antidepressants. Psychoneuroendocrinology, 2008.
147. Kokras, N.; Sotiropoulos, I.; Pitychoutis, P.M.; Almeida, O.F.; Papadopoulou-Daifoti, Z. Citalopram-mediated anxiolysis and differing neurobiological responses in both sexes of a genetic model of depression. Neuroscience, 2011, 194, 62-71.
148. Xu, F.; Peng, D.; Tao, C.; Yin, D.; Kou, J.; Zhu, D.; Yu, B. Antidepression effects of Danggui-Shaoyao-San, a fixed combination of Traditional Chinese Medicine, on depression model in mice and rats. Phytomedicine, 2011, 18, 1130-1136.
149. Murphy, D.; Konopacka, A.; Hindmarch, C.; Paton, J.F.; Sweedler, J.V.; Gillette, M.U.; Ueta, Y.; Grinevich, V.; Lozic, M.; Japundzic-Zigon, N. The Hypothalamic-Neurohypophyseal System: From Genome to Physiology. J. Neuroendocrinol., 2012, 24, 539-553.
150. Murgatroyd, C.; Wu, Y.; Bockmuhl, Y.; Spengler, D. Genes learn from stress: How infantile trauma programs us for depression. Epigenetics, 2010, 5.
151. Zelena, D. Co-regulation and epigenetic dysregulation in schizophrenia and bipolar disorder in J. Minarovits and H.H. Niller (eds.), Patho-Epigenetics of Disease, Springer Science+Business Media New York, 2012, 281-348.
152. Zhang, L.; Hernandez, V.S.; Liu, B.; Medina, M.P.; Nava-Kopp, A.T.; Irles, C.; Morales, M. Hypothalamic vasopressin system regulation by maternal separation: its impact on anxiety in rats. Neuroscience, 2012, 215, 135-148.
153. Di Iorgi, N.; Napoli, F.; Allegri, A.E.; Olivieri, I.; Bertelli, E.; Gallizia, A.; Rossi, A.; Maghnie, M. Diabetes Insipidus - Diagnosis and Management. Horm. Res. Paediatr., 2012, 55(67), 429-432.
154. Lemmens-Gruber, R.; Kamyar, M. Vasopressin antagonists. Cell Mol. Life Sci., 2006, 63, 1766-1779.
155. Wesche, D.; Deen, P.M.; Knoers, N.V. Congenital nephrogenic diabetes insipidus: the current state of affairs. Pediatr. Nephrol., 2012.
156. Rabinstein, A.A. Vasopressin antagonism: potential impact on neurologic disease. Clin. Neuropharmacol., 2006, 29, 87-93.
157. Akerlund, M. Involvement of oxytocin and vasopressin in the pathophysiology of preterm labor and primary dysmenorrhea. Prog. Brain Res., 2002, 139, 359-365.
158. Hofman, M.A.; Swaab, D.F. Alterations in circadian rhythmicity of the vasopressin-producing neurons of the human suprachiasmatic nucleus (SCN) with aging. Brain Res., 1994, 651, 134-142.
159. Zhou, J.N.; Riemersma, R.F.; Unmehopa, U.A.; Hoogendijk, W.J.; van Heerikhuize, J.J.; Hofman, M.A.; Swaab, D.F. Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression. Arch. Gen. Psychiatry, 2001, 58, 655-662.
160. Park, H.J.; Chae, Y.; Kim, J.W.; Lee, H.; Chung, J.H. Effect of acupuncture on hypothalamic-pituitary-adrenal system in maternal separation rats. Cell Mol. Neurobiol., 2011, 31, 1123-1127.
161. Coccaro, E.F.; Kavoussi, R.J.; Hauger, R.L.; Cooper, T.B.; Ferris, C.F. Cerebrospinal fluid vasopressin levels: correlates with aggression and serotonin function in personality-disordered subjects. Arch. Gen. Psychiatry, 1998, 55, 708-714.
162. Fetissov, S.O.; Hallman, J.; Nilsson, I.; Lefvert, A.K.; Oreland, L.; Hokfelt, T. Aggressive behavior linked to corticotropin-reactive autoantibodies. Biol. Psychiatry, 2006, 60, 799-802.
163. Mai, J.K.; Berger, K.; Sofroniew, M.V. Morphometric evaluation of neurophysin-immunoreactivity in the human brain: pronounced inter-individual variability and evidence for altered staining patterns in schizophrenia. J. Hirnforsch, 1993, 34, 133-154.
164. Baron-Cohen, S.; Belmonte, M.K. Autism: a window onto the development of the social and the analytic brain. Annu. Rev. Neurosci., 2005, 28, 109-126.
165. Yirmiya, N.; Rosenberg, C.; Levi, S.; Salomon, S.; Shulman, C.; Nemanov, L.; Dina, C.; Ebstein, R.P. Association between the arginine vasopressin 1a receptor (AVPR1a) gene and autism in a family-based study: mediation by socialization skills. Mol. Psychiatry, 2006, 11, 488-494.
166. Gold, P.W.; Goodwin, F.K.; Reus, V.I. Vasopressin in affective illness. Lancet, 1978, 1, 1233-1236.
167. van Londen, L.; Goekoop, J.G.; van Kempen, G.M.; Frankhuijzen-Sierevogel, A.C.; Wiegant, V.M.; van der Velde, E.A.; De Wied, D. Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology, 1997, 17, 284-292.
168. Landgraf, R. The involvement of the vasopressin system in stressrelated disorders. CNS Neurol. Disord. Drug Targets, 2006, 5, 167-179.
169. Van Londen, L.; Goekoop, J.G.; Zwinderman, A.H.; Lanser, J.B.; Wiegant, V.M.; De Wied, D. Neuropsychological performance and plasma cortisol, arginine vasopressin and oxytocin in patients with major depression. Psychol. Med., 1998, 28, 275-284.
170. Garcia, F.D.; Coquerel, Q.; Kiive, E.; Dechelotte, P.; Harro, J.; Fetissov, S.O. Autoantibodies reacting with vasopressin and oxytocin in relation to cortisol secretion in mild and moderate depression. Prog. Neuropsychopharmacol Biol. Psychiatry, 2011, 35, 118-125.
171. Meynen, G.; Unmehopa, U.A.; van Heerikhuize, J.J.; Hofman, M.A.; Swaab, D.F.; Hoogendijk, W.J. Increased arginine vasopressin mRNA expression in the human hypothalamus in depression: A preliminary report. Biol. Psychiatry, 2006, 60, 892-895.
172. Purba, J.S.; Hoogendijk, W.J.; Hofman, M.A.; Swaab, D.F. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch. Gen. Psychiatry, 1996, 53, 137-143.
173. Raadsheer, F.C.; Tilders, F.J.; Swaab, D.F. Similar age related increase of vasopressin colocalization in paraventricular corticotropin-releasing hormone neurons in controls and Alzheimer patients. J. Neuroendocrinol., 1994, 6, 131-133.
174. van Londen, L.; Goekoop, J.G.; Kerkhof, G.A.; Zwinderman, K.H.; Wiegant, V.M.; De Wied, D. Weak 24-h periodicity of body temperature and increased plasma vasopressin in melancholic depression. Eur. Neuropsychopharmacol., 2001, 11, 7-14.
175. Inder, W.J.; Donald, R.A.; Prickett, T.C.; Frampton, C.M.; Sullivan, P.F.; Mulder, R.T.; Joyce, P.R. Arginine vasopressin is associated with hypercortisolemia and suicide attempts in depression. Biol. Psychiatry, 1997, 42, 744-747.
176. Merali, Z.; Kent, P.; Du, L.; Hrdina, P.; Palkovits, M.; Faludi, G.; Poulter, M.O.; Bedard, T.; Anisman, H. Corticotropin-releasing hormone, arginine vasopressin, gastrin-releasing peptide, and neuromedin B alterations in stress-relevant brain regions of suicides and control subjects. Biol. Psychiatry, 2006, 59, 594-602.
177. Gold, P.W.; Weingartner, H.; Ballenger, J.C.; Goodwin, F.K.; Post, R.M. Effects of 1-desamo-8-D-arginine vasopressin on behavior and cognition in primary affective disorder. Lancet, 1979, 2, 992-994.
178. Jacobsen, K.R.; Ranek, L.; Tygstrup, N. Liver function and blood flow in normal man during infusion of vasopressin. Scand J. Clin. Lab. Invest., 1969, 24, 279-284.
179. Elands, J.; de Kloet, E.R.; de Wied, D. Neurohypophyseal hormone receptors: relation to behavior. Prog. Brain Res., 1992, 91, 459-464.
180. Meller, W.H.; Kathol, R.C.; Jaeckle, R.S.; Lopez, J.F. Stimulation of the pituitary-adrenal axis with arginine vasopressin in patients with depression. J. Psychiatr. Res., 1987, 21, 269-277.
181. Dallman, M.F. Stress update Adaptation of the hypothalamicpituitary- adrenal axis to chronic stress. Trends Endocrinol. Metab., 1993, 4, 62-69.
182. Cole, M.A.; Kim, P.J.; Kalman, B.A.; Spencer, R.L. Dexamethasone suppression of corticosteroid secretion: evaluation of the site of action by receptor measures and functional studies. Psychoneuroendocrinology, 2000, 25, 151-167.
183. von Bardeleben, U.; Holsboer, F. Human corticotropin releasing hormone: clinical studies in patients with affective disorders, alcoholism, panic disorder and in normal controls. Prog. Neuropsychopharmacol. Biol. Psychiatry, 1988, 12 Suppl, S165-187.
184. Heuser, I.; Yassouridis, A.; Holsboer, F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J. Psychiatr. Res., 1994, 28, 341-356.
185. von Bardeleben, U.; Holsboer, F.; Stalla, G.K.; Muller, O.A. Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects. Life Sci., 1985, 37, 1613-1618.
186. Rubin, R.T.; O'Toole, S.M.; Rhodes, M.E.; Sekula, L.K.; Czambel, R.K. Hypothalamo-pituitary-adrenal cortical responses to low-dose physostigmine and arginine vasopressin administration: sex differences between major depressives and matched control subjects. Psychiatry Res., 1999, 89, 1-20.
187. Muller, M.B.; Landgraf, R.; Keck, M.E. Vasopressin, major depression, and hypothalamic-pituitary-adrenocortical desensitization. Biol. Psychiatry, 2000, 48, 330-333.
188. Gray, S.T.; Holbrook, E.H.; Najm, M.H.; Sadow, P.M.; Curry, W.T.; Lin, D.T. Syndrome of Inappropriate Antidiuretic Hormone Secretion in Patients with Olfactory Neuroblastoma. Otolaryngol Head Neck Surg., 2012, 147(1), 147-151.
189. De Bellis, M.D;, Gold, P.W.; Geracioti, T.D. Jr., Listwak, S.J.; Kling, M.A. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am. J. Psychiatry, 1993, 150, 656-657.
190. Altemus, M.; Cizza, G.; Gold, P.W. Chronic fluoxetine treatment reduces hypothalamic vasopressin secretion in vitro. Brain Res., 1992, 593, 311-313.
191. Stovall, R.; Brahm, N.C.; Crosby, K.M. Recurrent episodes of serotonin-reuptake inhibitor-mediated hyponatremia in an elderly patient. Consult. Pharm., 2009, 24, 765-768.
192. Druckenbrod, R.; Mulsant, B.H. Fluoxetine-induced syndrome of inappropriate antidiuretic hormone secretion: a geriatric case report and a review of the literature. J. Geriatr. Psychiatry Neurol., 1994, 7, 254-256.
193. Rottmann, C.N. SSRIs and the syndrome of inappropriate antidiuretic hormone secretion. Am. J. Nurs., 2007, 107, 51-58; quiz 58-9.
194. Suwa, A.; Wakeno, M.; Tajika, A.; Kato, M.; Sugimoto, T.; Nishida, K.; Sakai, S.; Fujiyama, Y.; Takekita, Y.; Kinoshita, T. Syndrome of inappropriate secretion of anti-diuretic hormone in an elderly depressive patient receiving paroxetine: a case report. Int. J. Geriatr. Psychiatry, 2010, 25, 433-434.
195. Ozturk, S.; Ozsenel, E.B.; Kazancioglu, R.; Turkmen, A. A case of fluoxetine-induced syndrome of inappropriate antidiuretic hormone secretion. Nat. Clin. Pract. Nephrol., 2008, 4, 278-282.
196. van West, D.; Del-Favero, J.; Aulchenko, Y.; Oswald, P.; Souery, D.; Forsgren, T.; Sluijs, S.; Bel-Kacem, S.; Adolfsson, R.; Mendlewicz, J.; Van Duijn, C.; Deboutte, D.; Van Broeckhoven, C.; Claes, S. A major SNP haplotype of the arginine vasopressin 1B receptor protects against recurrent major depression. Mol. Psychiatry, 2004, 9, 287-292.
197. Levinson, D.F. The genetics of depression: a review. Biol. Psychiatry, 2006, 60, 84-92.
198. Zink, C.F.; Stein, J.L.; Kempf, L.; Hakimi, S.; Meyer-Lindenberg, A. Vasopressin modulates medial prefrontal cortex-amygdala circuitry during emotion processing in humans. J. Neurosci., 2010, 30, 7017-7022.
199. Larabee, T.M.; Liu, K.Y.; Campbell, J.A.; Little, C.M. Vasopressors in cardiac arrest: A systematic review. Resuscitation, 2012, 83(8), 932-939.
200. Garcia-Pagan, J.C.; Reverter, E.; Abraldes, J.G.; Bosch, J. Acute variceal bleeding. Semin. Respir. Crit. Care Med., 2012, 33, 46-54.
201. Makaryus, A.N.; McFarlane, S.I. Diabetes insipidus: diagnosis and treatment of a complex disease. Cleve. Clin. J. Med., 2006, 73, 65-71.
202. Rilling, J.K.; Demarco, A.C.; Hackett, P.D.; Thompson, R.; Ditzen, B.; Patel, R.; Pagnoni, G. Effects of intranasal oxytocin and vasopressin on cooperative behavior and associated brain activity in men. Psychoneuroendocrinology, 2012, 37, 447-461.
203. Guastella, A.J.; Kenyon, A.R.; Alvares, G.A.; Carson, D.S.; Hickie, I.B. Intranasal arginine vasopressin enhances the encoding of happy and angry faces in humans. Biol. Psychiatry, 2010, 67, 1220-1222.
204. Arban, R. V1b receptors: new probes for therapy. Endocrinology, 2007, 148, 4133-4135.
205. Marques, J.S. Perspectives for the treatment of anemia in heart failure: is there a role for vasopressin antagonists? Congest. Heart Fail, 2012, 18, 1-3.
206. Overstreet, D.H.; Griebel, G. Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat. Pharmacol. Biochem. Behav., 2005, 82, 223-227.
207. Serradeil-LeGal, C.; Derick, S.; Brossard, G.; Manning, M.; Simiand, J.; Gaillard, R.; Griebel, G.; Guillon, G. Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals. Stress, 2003, 6, 199-206.
208. Letourneau, J.J.; Riviello, C.M.; Li, H.; Cole, A.G.; Ho, K.K.; Zanetakos, H.A.; Desai, H.; Zhao, J.; Auld, D.S.; Napier, S.E.; Thomson, F.J.; Goan, K.A.; Morphy, J.R.; Ohlmeyer, M.H.; Webb, M.L. Identification and optimization of novel 2-(4-oxo-2-arylquinazolin- 3(4H)-yl)acetamide vasopressin V3 (V1b) receptor antagonists. Bioorg. Med. Chem. Lett., 2010, 20, 5394-5397.
209. Craighead, M.; Milne, R.; Campbell-Wan, L.; Watson, L.; Presland, J.; Thomson, F.J.; Marston, H.M.; Macsweeney, C.P. Characterization of a novel and selective V1B receptor antagonist. Prog. Brain. Res., 2008, 170, 527-535.
210. Yi, J.H.; Shin, H.J.; Kim, H.J. V2 receptor antagonist; tolvaptan. Electrolyte Blood Press, 2011, 9, 50-54.
211. Rehberg, S.; Ertmer, C.; Lange, M.; Morelli, A.; Whorton, E.; Dunser, M.; Strohhacker, A.K.; Lipke, E.; Kampmeier, T.G.; Van Aken, H.; Traber, D.L.; Westphal, M. Role of selective V2- receptor-antagonism in septic shock: a randomized, controlled, experimental study. Crit. Care, 2010, 14, R200.
212. Manning, M.; Misicka, A.; Olma, A.; Bankowski, K.; Stoev, S.; Chini, B.; Durroux, T.; Mouillac, B.; Corbani, M.; Guillon, G. Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J. Neuroendocrinol., 2012, 24, 609-628.
213. Ryckmans, T. Modulation of the vasopressin system for the treatment of CNS diseases. Curr. Opin. Drug Discov. Devel., 2010, 13, 538-547.
214. Engelmann, M.; Wotjak, C.T.; Ebner, K.; Landgraf, R. Behavioral impact of intraseptally released vasopressin and oxytocin in rats. Exp. Physiol., 2000, 85 Spec No, 125S-130S.
215. Griffante, C.; Green, A.; Curcuruto, O.; Haslam, C.P.; Dickinson, B.A.; Arban, R. Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist. Br. J. Pharmacol., 2005, 146, 744-751.
216. Vlieghe, P.; Khrestchatisky, M. Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery. Med. Res. Rev., 2012, doi: 10.1002/med.21252. [Epub ahead of print].
217. Mustafa, S.; Pfleger, K.D. G protein-coupled receptor heteromer identification technology: identification and profiling of GPCR heteromers. J. Lab. Autom, 2011, 16, 285-291.
218. Weissleder, R.; Kelly, K.; Sun, E.Y.; Shtatland, T.; Josephson, L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat. Biotechnol., 2005, 23, 1418-1423.
219. Gray, S.J.; Woodard, K.T.; Samulski, R.J. Viral vectors and delivery strategies for CNS gene therapy. Ther. Deliv., 2010, 1, 517-534.
220. Waehler, R.; Russell, S.J.; Curiel, D.T. Engineering targeted viral vectors for gene therapy. Nat. Rev. Genet., 2007, 8, 573-587.